Form 4: Equillium COO Executes Stock Option Exercise and Sale

Equillium, Inc. Senior Vice President and COO Christine Zedelmayer exercised options and sold 14,584 shares of common stock.

Summary

• Christine Zedelmayer, Senior Vice President and COO of Equillium, Inc., exercised options to acquire 14,584 shares of common stock at a price of $0.785 per share.
• Following the acquisition, the reporting person sold the same 14,584 shares at a weighted average price of $2.9304 per share.
• The transactions were executed on June 5, 2026, pursuant to a Rule 10b5-1 trading plan adopted on August 27, 2025.
• Post-transaction, the reporting person retains beneficial ownership of 62,586 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was conducted under a pre-established 10b5-1 plan and represents standard executive financial planning.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating a systematic approach to equity management rather than reactive selling.
• The sale price of $2.9304 represents a significant premium over the exercise price of $0.785.

Negatives

• The transaction results in a reduction of the executive's direct equity stake in the company.

Risks

• Future share price volatility could impact the value of remaining holdings.
• Reliance on Rule 10b5-1 plans does not eliminate market risk for the reporting person.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard practice in the biotechnology sector, often used by executives to manage personal liquidity and diversify holdings without signaling negative sentiment regarding company prospects.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard governance practice for executives in the pharmaceutical and biotech industries to avoid potential insider trading concerns.
• The volume of shares sold is relatively small compared to the total outstanding shares of typical small-cap biotech firms.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and executed at market prices.

Next Steps

• No further actions or milestones were disclosed in this filing.

Key Dates

Keywords

Equillium, EQ, Insider Trading, Form 4, Stock Options, Biotech